

# ARD

Annals of the Rheumatic Diseases  
The EULAR Journal

## Editor

Leo van de Putte (Nijmegen)

## Associate editors

Thomas Bardin (Paris)  
Johannes Bijlsma (Utrecht)  
Gerd Burmester (Berlin)  
Bevrah Hahn (Los Angeles)  
Frank Wollheim (Lund)  
Anthony Woolf (Truro)

## Methodological adviser

Paco Welsing (Nijmegen)

## Editorial board

Martin Aringer (Vienna)	W Maslinski (Poland)
Paul Bacon (Birmingham)	Marco Matucci Cerinic (Florence)
Francis Berenbaum (Paris)	Kusuki Nishioka (Kanagawa)
Maarten Boers (Amsterdam)	Seza Özen (Ankara)
Dimitrios Boumpas (Heraklion)	Thomas Pap (Magdeburg)
Barry Bresnihan (Dublin)	Eliseo Pascual Gómez (Alicante)
Hillary Capell (Glasgow)	Leonardo Punzi (Padova)
Maurizio Cutolo (Genova)	Lars Rönnblom (Uppsala)
Gary Firestein (La Jolla San Diego)	Blaž Rozman (Ljubljana)
Philippe Goupille (Tours)	Georg Schett (Vienna)
Ellen Gravallese (Boston)	José Da Silva (Coimbra)
Wolfgang Gross (Bad Bramstedt)	Hendrik Schulze-Koops (Erlangen)
Francis Guillemain (Nancy)	Alex So (Lausanne)
Gabriel Herrero-Beaumont (Madrid)	Tuulikki Sokka (Nashville)
Frederic Houssiau (Brussels)	Deborah Symmons (Manchester)
Tom Huizinga (Leiden)	Paul-Peter Tak (Amsterdam)
Christian Jorgensen (Montpellier)	Alan Tyndall (Basel)
George Kollias (Athens)	Athanasios Tzioufas (Athens)
Tore Kvien (Oslo)	Jifi Vencovsky (Praag)
Marjatta Leirisalo-Repo (Lund)	Michael Ward (Bethesda)
Frank Luitjen (Leuven)	Michael Weisman (Los Angeles)
Hanns-Martin Lorenz (Heidelberg)	Hasan Yazici (Istanbul)
	Editor, <i>BMJ</i>

## Advisory committee

Wim vd Berg (Nijmegen)	Peter Lipsky (Dallas)
Stefano Bombardieri (Pisa)	Stefan Lohmander (Lund)
Ferdinand Breedveld (Leiden)	Ravinder Maini (London)
Leslie Crofford (Michigan)	Emilio Martin Mola (Madrid)
Jean-Michel Dayer (Geneva)	Haralampos Moutsopoulos (Athens)
Mike Doherty (Nottingham)	James O'Dell (Omaha)
Maxime Dougados (Paris)	Karel Pavelka (Prague)
John Edmonds (Sydney)	Josef Rovensky (Piestany)
Paul Emery (Leeds)	Yehuda Shoenfeld (Tel-Hashomer)
Daniel Furst (Seattle)	Josef Smolen (Vienna)
Steffen Gay (Zurich)	Walther van Venrooy (Nijmegen)
Joachim Kalden (Erlangen)	Eric Veys (Gent)
Edward Keystone (Toronto)	Allan Wiik (Denmark)
Lars Klareskog (Stockholm)	

## Instructions to authors

Full instructions are available online at [www.annrheumdis.com/misc/ifora.shtml](http://www.annrheumdis.com/misc/ifora.shtml)  
If you do not have web access please contact the editorial office:  
Email: [annrheumdis.edoff@worldonline.nl](mailto:annrheumdis.edoff@worldonline.nl)

## Subscription information


See inside back cover

## Copyright

© 2004 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of *Annals of the Rheumatic Diseases*

Authors are required to grant *Annals of the Rheumatic Diseases* an exclusive licence to publish; further details available online at [www.annrheumdis.com/misc/ifora.shtml](http://www.annrheumdis.com/misc/ifora.shtml)

• *Annals of the Rheumatic Diseases* is published by BMJ Publishing Group, typeset by The Charlesworth Group, and printed in the UK on acid-free paper by Thanet Press, Margate  
• Periodicals postage paid, Rahway, NJ. Postmaster: send address changes to: *Annals of the Rheumatic Diseases*, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA



## contents ARD

Volume 63 Supplement II November 2004

### Preface

- ii1 Advances in targeted therapies VI *F C Breedveld, J R Kalden, J S Smolen*

### Consensus statement

- ii2 Updated consensus statement on biological agents, specifically tumour necrosis factor  $\alpha$  (TNF $\alpha$ ) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004 *D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J W J Bijlsma, M Dougados, P Emery, E C Keystone, L Klareskog, P J Mease*

### Warm-up

- ii13 Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues *F Wolfe, K Michaud, E M DeWitt*
- ii18 Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection *L H Calabrese, N Zein, D Vassilopoulos*

### Genetics

- ii25 Pharmacogenetics in the rheumatic diseases *B N Cronstein*
- ii28 What precedes development of rheumatoid arthritis? *L Klareskog, L Alfredsson, S Rantapää-Dahlqvist, E Berglin, P Stolt, L Padyukov*

### Clinical aspects

- ii32 Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa? *T Pincus, T Sokka*
- ii40 The International Classification of Functioning, Disability and Health (ICF) Core Sets for rheumatoid arthritis: a way to specify functioning *G Stucki, A Cieza*
- ii46 Should infection still be considered as the most likely triggering factor for rheumatoid arthritis? *S M Carty, N Snowden, A J Silman*
- ii50 New issues in tuberculosis *S H E Kaufmann*

### New targets I—signal transduction

- ii57 Nuclear factor (NF)- $\kappa$ B proteins: therapeutic targets *I M Verma*
- ii62 Mitogen activated protein kinases as targets for development of novel anti-inflammatory drugs *M Karin*
- ii65 B cell signalling as therapeutic target *R H Carter*
- ii67 Targeting the Jak/STAT pathway for immunosuppression *J J O'Shea*

### New targets II

- ii72 DREAMing about arthritic pain *H-Y M Cheng, J M Penninger*

**NEW**  
**ONLINE**  
**SUBMISSION**  
**GO TO**  
**WEBSITE**  
**TO SUBMIT YOUR**  
**MANUSCRIPT**

.....	ii90	Toll-like receptors in rheumatoid arthritis joint destruction mediated by two distinct pathways <i>C Ospelt, D Kyburz, M Pierer, R Seibl, M Kurowska, O Distler, M Neidhart, U Muller-Ladner, T Pap, R E Gay, S Gay</i>
<b>New targets III—pathways</b>		
ii76 A toll for T cell costimulation <i>F Y Liew, M Komai-Koma, D Xu</i>		
.....		
<b>New target disease</b>		
ii79 The utility of tumour necrosis factor blockade in orphan diseases <i>E C Keystone</i>	ii92	Defining a role for fibroblasts in the persistence of chronic inflammatory joint disease <i>C D Buckley, A Filer, O Haworth, G Parsonage, M Salmon</i>
.....		
<b>New targets IV</b>		
ii84 Chemokines: role in inflammation and immune surveillance <i>B Moser, K Willimann</i>	ii96	Cell therapy for autoimmune diseases: does it have a future? <i>A Radbruch, A Thiel</i>